Popular on EntSun
- UK Financial Ltd Announces A Special Board Meeting Today At 4PM: Orders MCAT Lock on CATEX, Adopts ERC-3643 Standard, & Cancels $0.20 MCOIN for $1 - 212
- Guests Can Save 10 Percent Off New Vacation Rental Homes at KeysCaribbean's Village at Hawks Cay Villas - 192
- Cut Costs & Boost Profits with the First Major Upgrade in 30 YEARS Replacing Rotary Lasers and Historic Clear Tube Altimeter Bubbles - 188
- Metro Detroit teen Lola Winters turns viral TikTok fame into a sold-out clothing brand - 172
- MROVI Trailer Parts Launches Its Own Tire Brand: Introducing MROVI Tires and the New Didgori Trail Tread - 152
- America's Leading Annuity Expert Carlton Cap Averil II Joins Tom Hegna on "Financial Freedom with Tom Hegna" - 139
- Touch Massage London Unveils Premium Local Massage Services to Transform Wellbeing Across the Capital - 130
- ProfileSpider Launches Powerful One-Click Profile Scraper for Recruiters and Growth Teams - 130
- Make This Fall Your Most Stylish Yet with Nickel-Free Bestsellers from Nickel Smart - 124
- Verb™ Presents Features Vanguard Personalized Indexing: Utilizing Advanced Tax-Loss Harvesting Technology - 116
Similar on EntSun
- VSee Health (N A S D A Q: VSEE) Secures $6.0M At-Market Investment, Accelerates Expansion as Revenues Surge
- High-Conviction CNS Disruptor Aiming to Transform Suicidal Depression, Ketamine Therapeutics, and TMS - Reaching Millions by 2030
- OKAVA Pharmaceuticals Announces First Cat Dosed in MEOW-1 Study of OKV-119, the World's First Clinical-Stage GLP-1 Weight-Loss Therapy for Pets
- FDA Accepts ANDA for KETAFREE™ as Analyst Sets $34 Price Target for NRx Pharmaceuticals: (N A S D A Q : NRXP) NRx is Poised for a massive Breakthrough
- Revenue Expansion, Regulatory Momentum, and a Leadership Position in the $750 Million Suicidal Depression: NRx Pharmaceuticals (N A S D A Q: NRXP)
- $750 Million Market on Track to $3.35 Billion by 2034: $NRXP Launches First-in-Florida "One Day" Depression Treatment in Partnership with Ampa Health
- $750 Million Market Set to Soar to $3.35 Billion by 2034 as Florida Launches First-in-Nation One-Day: NRx Pharmaceuticals (N A S D A Q: NRXP) $NRXP
- U.S. Entrepreneur Anjo De Heus Builds Innovation Bridge Between America and the Gulf
- Phinge's Netverse to Redefine Clinical Trial Safety and Data Integrity with Netverse Patented, Hardware-Verified Platform
- MDRN MUSE Expands Insurance Network Coverage to Include Delta Dental & Cigna
Metavalis Inc. Initiates Formation of Scientific Advisory Board for Non Viral Gene Therapy Asset
EntSun News/11079719
Bioengineering firm recruiting founding advisors in Lipid Physics, Hepatology, and Regulatory Affairs to guide its Smart LNP 3.0 platform and Dec 24th IP filing.
BRANSON, Mo. - EntSun -- Following the scheduled filing of foundational intellectual property for its Smart LNP 3.0 platform a novel biodegradable ionizable lipid polysarcosine conjugate Metavalis is moving to appoint four strategic partners to guide the asset through pre clinical validation and FDA Pre IND pathways.
"We are assembling a council of technical architects, not just observers," said Jordan Bekemeier, Founder of Metavalis. "Our platform is engineered to solve the Redosing Bottleneck in gene therapy for Crigler-Najjar Syndrome. We are seeking equity aligned partners who possess deep domain expertise in non viral delivery physics and regulatory strategy."
Open Advisory Seats:
Metavalis is currently accepting inquiries for the following strategic roles:
The LNP Architect (Formulation Science): Seeking Ph.D. leadership in biodegradable lipid kinetics and extra-hepatic delivery, specifically regarding Polysarcosine lipid conjugates.
The Clinical Lead (Hepatology): Seeking an M.D./Ph.D. with principal investigator experience in metabolic liver disease trials (CNS1/Urea Cycle Disorders).
More on EntSun News
The Regulatory Strategist (Compliance): Seeking former FDA CBER reviewers or regulatory consultants with specific expertise in non viral gene therapy IND applications.
The Polymer Chemist (Materials Science): Seeking expertise in Stealth polymer synthesis to replace PEG architectures.
About Metavalis Inc.
Metavalis Inc. is a biotechnology company focused on the development of non viral genetic medicines. The company integrates the Universal Constructor Protocol, a sovereign quantum neuromorphic AI architecture, to optimize biological delivery vectors.
Contact Information:
Qualified candidates and researchers interested in strategic partnership may contact the executive office directly.
You can also Apply on LinkedIn at:
https://www.linkedin.com/jobs/view/4327214946
Contact: Jordan Bekemeier, Founder & CEO
Email: jordan@metavalis.com
Website: https://metavalis.com/
Forward Looking Statements
This press release contains forward looking statements regarding the company's recruitment plans and investigational technologies. These statements are subject to risks and uncertainties.
"We are assembling a council of technical architects, not just observers," said Jordan Bekemeier, Founder of Metavalis. "Our platform is engineered to solve the Redosing Bottleneck in gene therapy for Crigler-Najjar Syndrome. We are seeking equity aligned partners who possess deep domain expertise in non viral delivery physics and regulatory strategy."
Open Advisory Seats:
Metavalis is currently accepting inquiries for the following strategic roles:
The LNP Architect (Formulation Science): Seeking Ph.D. leadership in biodegradable lipid kinetics and extra-hepatic delivery, specifically regarding Polysarcosine lipid conjugates.
The Clinical Lead (Hepatology): Seeking an M.D./Ph.D. with principal investigator experience in metabolic liver disease trials (CNS1/Urea Cycle Disorders).
More on EntSun News
- Microgaming Unveils Red Papaya: A New Studio Delivering Cutting-Edge, Feature-Rich Slots
- BOHO Design Rentals Launches Luxury Sofa Rentals in Denver
- Bay Street Yard announces New Year's Eve Celebration
- 5-Star Duncan Injury Group Expands Personal Injury Representation to Arizona
- The End of "Influencer" Gambling: Bonusetu Analyzes Finland's Strict New Casino Marketing Laws
The Regulatory Strategist (Compliance): Seeking former FDA CBER reviewers or regulatory consultants with specific expertise in non viral gene therapy IND applications.
The Polymer Chemist (Materials Science): Seeking expertise in Stealth polymer synthesis to replace PEG architectures.
About Metavalis Inc.
Metavalis Inc. is a biotechnology company focused on the development of non viral genetic medicines. The company integrates the Universal Constructor Protocol, a sovereign quantum neuromorphic AI architecture, to optimize biological delivery vectors.
Contact Information:
Qualified candidates and researchers interested in strategic partnership may contact the executive office directly.
You can also Apply on LinkedIn at:
https://www.linkedin.com/jobs/view/4327214946
Contact: Jordan Bekemeier, Founder & CEO
Email: jordan@metavalis.com
Website: https://metavalis.com/
Forward Looking Statements
This press release contains forward looking statements regarding the company's recruitment plans and investigational technologies. These statements are subject to risks and uncertainties.
Source: Metavalis
0 Comments
Latest on EntSun News
- Golden Paper Identifies Global Growth in Packaging Papers and Upgrades Its High-End Production Capacity
- Live Performance at the Bal Theater by Angel Sessions
- Detroit-Born Puzzle Game Launches Nationwide XIXMAS Challenge With Gaming PC Giveaway
- Champagne, Caviar Bumps & Pole Performances — Welcome the New Year Early with HandPicked Social Club
- A New Soul Album: Heart Of Kwanzaa, 7-Day Celebration
- Allegiant Management Group Named 2025 Market Leader in Orlando by PropertyManagement.com
- NAFMNP Awarded USDA Cooperative Agreement to Continue MarketLink Program Under FFAB
- Costa Oil - 10 Minute Oil Change Surpasses 70 Locations with Construction of San Antonio, TX Stores — Eyes Growth Via Acquisition or Being Acquired
- LaTerra and Respark Under Contract with AIMCO to Acquire a $455M, 7-Property Chicago Multifamily Portfolio
- Amazing Hotels Inc Announces A Luxury Hotel & Entertainment Complex On 500+/- Lakefront Acres
- Record Revenue, Tax Tailwinds, and AI-Driven Scale: Why Off The Hook YS Inc. Is Emerging as a Standout in the $57 Billion U.S. Marine Market
- VSee Health (N A S D A Q: VSEE) Secures $6.0M At-Market Investment, Accelerates Expansion as Revenues Surge
- Children Rising Appoints Marshelle A. Wilburn as New Executive Director
- New 'Christmas Werx' Album by Higginswerx Yields Five Music Videos
- Fairmint CEO Joris Delanoue Elected General Director of the Canton Foundation
- Sleep Basil Mattress Co.'s Debuts New Home Page Showcasing Performance Sleep Solutions for Active Denver Lifestyles
- Bent Danholm Joins The American Dream TV as Central Florida Host
- Sip and Frost Cake Bar Announces New Partnership with Tommy Nobis Center Academy
- The Nature of Miracles Celebrates 20th Anniversary Third Edition Published by DreamMakers Enterprises LLC
- Artificial Intelligence Leader Releases Children's Book on Veterans Day